<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibodies</z:hpo> (aPL) represent a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> population reacting with negatively charged, less frequently neutral <z:chebi fb="1" ids="16247">phospholipids</z:chebi> and/or <z:chebi fb="0" ids="16247">phospholipid</z:chebi>-binding serum proteins </plain></SENT>
<SENT sid="1" pm="."><plain>The study was made of antibodies to a wide spectrum of <z:chebi fb="1" ids="16247">phospholipids</z:chebi>: to negatively charged <z:chebi fb="1" ids="16247">phospholipids</z:chebi> such as phosphatide acid (aPA), <z:chebi fb="0" ids="28494">cardiolipin</z:chebi> (aCL), <z:chebi fb="0" ids="49183">phosphatidylcholine</z:chebi> (aPS), phosphatidylinositol (aPI), <z:chebi fb="0" ids="17517">phosphatidylglycerol</z:chebi> (aPG) and to neutrally charged <z:chebi fb="0" ids="16247">phospholipid</z:chebi>--<z:chebi fb="0" ids="49183">phosphatidylcholine</z:chebi> (aPC)--in 54 patients with <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE) and 29 patients with <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> (PAPS) </plain></SENT>
<SENT sid="2" pm="."><plain>The test for <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> (LAC) was also made </plain></SENT>
<SENT sid="3" pm="."><plain>aPL in SLE patients free of <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> were detected in 61, 36 and 9% (aPC, aPS and aPA, aCL, respectively) </plain></SENT>
<SENT sid="4" pm="."><plain>aPI and aPG did not exceed <z:mpath ids='MPATH_458'>normal</z:mpath> values </plain></SENT>
<SENT sid="5" pm="."><plain>81% of SLE patients with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> were LAC positive and 88% aPL positive </plain></SENT>
<SENT sid="6" pm="."><plain>60, 53, 44, 40, 13 and 17 were positive to aPC, aPA, aPS, aCL, aPG and aPI, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Among patients with PAPS, the highest positivity was by LAC, occurrence of the other aPL was the same as in SLE patients with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>aCL, aPA, aPC, aPS, aPG and aPI were found in 55, 52, 41, 38, 31 and 21% of cases, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>In clinical manifestations of <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> and negative tests for LAC and aCL it is advisable to make tests for aPS and aPC </plain></SENT>
<SENT sid="10" pm="."><plain>aPC occur in SLE patients more frequently than the other aPL: in 63% of SLE patients free of <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> and in 60% of SLE patients with this syndrome </plain></SENT>
<SENT sid="11" pm="."><plain>Antibodies to other <z:chebi fb="1" ids="16247">phospholipids</z:chebi>, but not to <z:chebi fb="0" ids="28494">cardiolipin</z:chebi>, were present in SLE + APS in half of the cases but in SLE + PAPS in one third of the patients </plain></SENT>
<SENT sid="12" pm="."><plain>Occurrence of aCL in the serum of SLE + PAPS patients is associated with the presence of antibodies to any other <z:chebi fb="0" ids="16247">phospholipid</z:chebi> irrespective of the charge </plain></SENT>
<SENT sid="13" pm="."><plain>The severity of vascular changes did not correlate with the number of aPL variant found in the serum </plain></SENT>
</text></document>